ARDS、肺炎与脓毒症联盟:危重症综合征表型分型的国家平台原理、设计与可行性
美国国立卫生研究院建立ARDS、肺炎与脓毒症(APS)联盟表型研究,为多中心、纵向、前瞻性观察性队列,计划4年入组4000例危重症成人。前1000例在不足13个月内提前完成入组,生物样本采集率高,专家裁定分类为ARDS 40%、肺炎52%、脓毒症89%。
要点
- 前1000例提前入组,中位年龄64岁,75%用血管加压药,50%接受有创机械通气。
- 生物样本采集率高:血99%、上呼吸道拭子98%、下呼吸道37%、尿80%、胃肠道65%。
- 专家裁定分类为ARDS 40%、肺炎52%、脓毒症89%,支持按生物学特征细分综合征。
核心结论
- APS联盟表型研究正在构建疾病严重度高、数据与生物样本丰富的ARDS、肺炎与脓毒症危重症成人队列,并将继续完成4000例入组。
研究设计与样本
- 多中心、纵向、前瞻性、观察性队列研究,计划4年内入组4000例ARDS、肺炎或脓毒症危重症成人。
- 可行性通过评估前1000例的入组速度、参与者特征、生物样本采集及专家裁定确诊比例来评价。
主要发现
- 前1000例在不足13个月内提前完成入组,中位年龄64岁,75%接受血管加压药,50%接受有创机械通气,25%在入组后4周内院内死亡。
- 生物样本采集率:血99%、上呼吸道拭子98%、下呼吸道样本37%、尿80%、胃肠道样本65%。
- 专家裁定结果:40%分类为ARDS,52%分类为肺炎,89%分类为脓毒症。
关键数值与推荐
- 前1000例入组时间小于13个月(提前于计划)。
- 专家裁定分类:ARDS 40%、肺炎52%、脓毒症89%。
临床怎么用
- 该平台可为ARDS、肺炎与脓毒症提供统一采集的纵向数据与生物样本,支持基于生物学特征的亚型分型研究。
- 临床可关注其表型分型结果对未来危重症综合征精准诊疗与临床试验入组策略的影响。
局限性
- 可行性基于前1000例评估,尚非全部4000例入组结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To enhance biological understanding of ARDS, pneumonia, and sepsis and to accelerate therapeutic development in these areas, the National Institutes of Health developed the ARDS, Pneumonia, and Sepsis (APS) Consortium. RESEARCH QUESTION: Is the APS Consortium study rapidly generating data and biospecimens from a large cohort of critically ill adults with ARDS, pneumonia, and sepsis that will facilitate phenotyping of these syndromes? STUDY DESIGN AND METHODS: The APS Consortium Phenotyping Study is a multicenter, longitudinal, prospective, observational cohort study aimed at enrolling 4,000 critically ill adults with ARDS, pneumonia, or sepsis over 4 years. Data and biospecimens are collected to characterize many aspects of each participant's chronic health, acute illness, and long-term recovery to facilitate phenotyping, that is, subclassifying ARDS, pneumonia, and sepsis into precise biologically based subsets with shared pathophysiologic characteristics. Feasibility of the study was assessed by evaluating the first 1,000 participants in terms of recruitment pace, participant characteristics, biospecimen collection, and proportion with confirmed ARDS, pneumonia, and sepsis based on expert adjudication. RESULTS: The first 1,000 participants were recruited ahead of schedule in < 13 months. Median age was 64 years, 75% received vasopressors, 50% received invasive mechanical ventilation, and 25% died in the hospital within 4 weeks of enrollment. Biospecimen collection rates were high, with 99% of participants with blood samples, 98% with upper respiratory swabs, 37% with lower respiratory samples, 80% with urine samples, and 65% with gastrointestinal samples. Expert adjudication resulted in 40% classified with ARDS, 52% classified with pneumonia, and 89% classified with sepsis. INTERPRETATION: The APS Consortium Phenotyping Study is producing a cohort of critically ill adults with ARDS, pneumonia, and sepsis with high severity of disease and a rich set of data and biospecimens. The study will continue to full enrollment of 4,000 participants. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT06521502; URL: www. CLINICALTRIALS: gov.
引用
- Self WH, Calfee CS, Brown SM, et al. The ARDS, Pneumonia, and Sepsis Consortium: Rationale, Design, and Feasibility of a National Platform for Phenotyping Critical Illness Syndromes. Chest. 2026. PMID: 42442528. doi:10.1016/j.chest.2026.05.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。